Current Report Filing (8-k)
November 05 2019 - 4:55PM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event
reported): November 5, 2019 (October 30, 2019)
CALMARE THERAPEUTICS INCORPORATED
(Exact name of registrant as specified in its
charter)
Delaware
|
|
001-08696
|
|
36-2664428
|
(State or other jurisdiction
|
|
(Commission File Number)
|
|
(IRS Employer
|
of Incorporation)
|
|
|
|
Identification Number)
|
|
|
1375 Kings Highway East
|
|
|
|
|
Fairfield, CT 06824
|
|
|
|
|
(Address of principal executive offices)
|
|
|
|
|
203-368-6044
|
|
|
|
|
(Registrant’s Telephone Number)
|
|
|
N/A
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
None
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
|
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
As set forth in the Registrant’s Form
10-K for the fiscal year ended December 31, 2016 (the “2016 10-K”), on August 22, 2014, GEOMC filed a complaint against
the Registrant in the United States District Court for the District of Connecticut. The allegations included in that complaint,
as amended, are described in the 2016 10-K. On September 29, 2017, the District Court entered a final judgment that awarded GEOMC,
among other relief, monetary damages of $4,673,406, in addition to pre-judgment interest of $5,678,764, with both amounts totaling
$10,352,170. On May 25, 2018, the District Court entered an order awarding GEOMC attorneys’ fees in the amount of $836,442.05
and costs in the amount of $5,231.80.
Calmare appealed both the final judgment and
the May 25, 2018 order awarding GEOMC attorneys’ fees and costs to the United States Court of Appeals for the Second Circuit.
As set forth in the Registrant’s Forms 8-K dated March 18, 2019 and dated June 10, 2019, the United States Court of Appeals
for the Second Circuit on March 12, 2019 vacated the District Court’s judgment and remanded the case to the District Court
for further proceedings.
On October 30, 2019, the United States Court
of Appeals for the Second Circuit vacated the District Court’s May 25, 2018 order awarding GEOMC attorneys’ fees and
costs and remanded the case to the District Court for further proceedings.
The information in this Item 8.01 of this
Form 8-K is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange
Act of 1934, or otherwise subject to the liabilities of that section. The information in this Item 8.01 of this Form 8-K also
shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities
Exchange Act of 1934, except to the extent that the Company specifically incorporates it by reference.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.
November 5, 2019
|
|
|
|
|
By:
|
/s/ Conrad Mir
|
|
|
Conrad Mir
Chief
Executive Officer
|
Calmare Therapeutics (CE) (USOTC:CTTC)
Historical Stock Chart
From Apr 2024 to May 2024
Calmare Therapeutics (CE) (USOTC:CTTC)
Historical Stock Chart
From May 2023 to May 2024